Literature DB >> 26629266

Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer.

Loretta Fala.   

Abstract

Entities:  

Year:  2015        PMID： 26629266      PMCID： PMC4665044     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  4 in total

Review 1.  The VEGF family in cancer and antibody-based strategies for their inhibition.

Authors:  Laura A Sullivan; Rolf A Brekken
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

2.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

3.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors:  Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal:  Lancet       Date:  2014-06-02       Impact factor: 79.321

4.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316
  4 in total
  5 in total

1.  Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.

Authors:  Anne Steins; Eva A Ebbing; Marcel C M Pistorius; Cynthia Waasdorp; Kausilia K Krishnadath; Jan Paul Medema; Johanna W Wilmink; Ron A A Mathôt; Maarten F Bijlsma; Hanneke W M van Laarhoven
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.

Authors:  Biao Gu; WenChuang Gao; HongJun Chu; Jian Gao; Zhi Fu; Hui Ding; JunJie Lv; QingQuan Wu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 3.  Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches.

Authors:  Yuefei Jin; Wangquan Ji; Haiyan Yang; Shuaiyin Chen; Weiguo Zhang; Guangcai Duan
Journal:  Signal Transduct Target Ther       Date:  2020-12-24

Review 4.  Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.

Authors:  Meng Niu; Duo Hong; Teng-Chuang Ma; Xiao-Wei Chen; Jin-Hang Han; Jun Sun; Ke Xu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

Review 5.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.